A Deep Dive Into The Game-Changing Drugs For Skin Diseases
Executive Summary
Scrip's Kevin Grogan joins Datamonitor's Pamela Spicer and Davinderpreet Mangat to discuss the skin disease landscape and whether atopic dermatitis is now where psoriasis was a decade ago as another wave of innovative products start to reach the market.
You may also be interested in...
Big Year For UCB As Bimzelx Awaits US Green Light
The Brussels-based company's head of immunology has told Scrip that going into a crowded market against several highly effective biologics across different classes holds no fears for UCB despite some concerns that US prescribers will stick to what they know when it comes to psoriasis therapies.
Executives On The Move: NervGen Pharma, Janux Therapeutics and More
Recent executive moves in the industry include C-suite changes at NervGen Pharma and Phathom Pharmaceuticals and Clarity Pharmaceuticals. Meanwhile, new directors were appointed at Janux Therapeutics and PepGen.
Pipeline Watch: 22 Approvals And 15 Trial Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.